| Revenue | 161,650.93a | 144,645.38a |
| Cost of sales (-) | -102,203.93a | -113,071.6a |
| Gross profit | 59,447a | 31,573.78a |
| General administrative expenses (-) | -19,767.09a | -18,800.76a |
| Marketing, sales and distribution expenses (-) | -14,688.37a | -14,991.03a |
| Research and development expenses (-) | -1,975.7a | -1,869.84a |
| Other operating income | 5,717.44a | 4,440.07a |
| Other operating expense (-) | -3,448.76a | -7,366.51a |
| Operating profit / (loss) | 25,284.52a | -7,014.28a |
| Impairment losses and reversals of impairment losses determined in accordance with IFRS 9, net | -675a | -558.07a |
| Investment activity income | 4,138.68a | 6,756.48a |
| Investment activity expenses (-) | -9.49a | -68.52a |
| Profit / (loss) before financing expense | 28,738.71a | -884.39a |
| Finance income | 3,873.15a | 17,467.29a |
| Finance costs (-) | -31,355.83a | -45,658.15a |
| Monetary gain / (loss) | 23,398.71a | 34,027.78a |
| Profit before tax | 24,654.74a | 4,952.53a |
| Tax (expense) / income | — | — |
| Current period tax expense | -855.65a | -392.32a |
| Deferred tax income / (expense) | -15,342.95a | 19,149.02a |
| Profit for the year | 8,456.15a | 23,709.24a |